Why Effective Project Governance Matters in Global Pharmacovigilance

    Why Effective Project Governance Matters in Global Pharmacovigilance

    Vigilance Pharma & Biotech

    Friday, 19 September 2025

    person-image

    Almudena Soriano, Senior Consultant Drug Safety at QbD Group

    share-iconshare-icon-mob Share

    X (Twitter) icon\ \ X (Twitter) LinkedIn icon\ \ LinkedIn WhatsApp icon\ \ WhatsApp Copy link icon\ \ Copy link Mail icon\ \ Mail

    Discover why effective project governance is key to global pharmacovigilance. Ensure compliance, transparency, and patient safety across markets.

    Play

    Effective Project Governance in Global Pharmacovigilance | QbD Group

    AI-generated audio

    4:50

    Pharmacovigilance (PV) is no longer just a regulatory requirement; it has become a strategic business imperative. For companies operating internationally, safety oversight must align with diverse local regulations, global health authority expectations, and fast-evolving technologies.

    In this complex environment, effective project governance is the foundation for compliance, efficiency, and patient safety. For organizations considering outsourcing PV activities, understanding the value of strong governance, and selecting a partner that can deliver it, is essential.

    1. Accountability and Clear Oversight

    Strong governance ensures every stakeholder knows their role and responsibilities. In global PV, this often means coordinating across affiliates, CROs, and partners, while maintaining a single point of accountability.

    By outsourcing pharmacovigilance to a specialized provider, companies benefit from established governance structures: clear reporting lines, escalation pathways, and oversight mechanisms. This reduces compliance risks and facilitates seamless interactions with regulators.

    2. Harmonizing Global Processes with Local Needs

    Regulatory requirements vary widely. Some countries demand a full local PV presence, while others focus on harmonized reporting. Without effective governance, these differences can lead to costly inconsistencies.

    Outsourcing to an expert partner provides access to a global governance framework designed to harmonize processes while tailoring compliance to each market. This balance minimizes risk while optimizing operational efficiency.

    3. Enabling Cross-Functional Collaboration

    Pharmacovigilance touches nearly every part of a biopharma organization — clinical operations, regulatory affairs, medical affairs, and quality assurance. Governance frameworks make these interactions structured and predictable.

    An outsourcing partner can act as the central hub, facilitating communication, ensuring alignment across departments, and providing dashboards or KPIs that highlight performance and compliance in real time.

    4. Managing Outsourcing Without Losing Control

    Some companies hesitate to externalize PV due to concerns about visibility. In reality, strong governance provides more transparency, not less.

    Effective partners establish steering committees, governance boards, and regular review meetings. Sponsors maintain full control over decision-making, while freeing internal teams from day-to-day operational burdens.

    5. Supporting Clinical Development and Post-Marketing Safety

    From clinical trials to post-marketing surveillance, governance provides consistency across the entire product lifecycle.

    Outsourced PV partners bring proven experience in trial oversight, risk management planning, and real-world evidence collection, ensuring that no safety milestone is overlooked, even with limited in-house resources.

    6. Driving Quality, Audit Readiness, and Continuous Improvement

    Governance frameworks also underpin quality management. CAPA follow-up, audit readiness, and regulatory intelligence are integrated into daily processes.

    This proactive approach means companies benefit from ongoing process improvements and are always ready for inspections, rather than reacting after findings.

    7. Leveraging Technology Securely

    Modern PV depends heavily on digital solutions— automation, AI, and cloud-based safety systems. Implementing and validating these requires strict governance to maintain data integrity and compliance.

    By outsourcing, companies gain immediate access to validated tools and governance frameworks, reducing implementation costs and risks.

    8. Strategic Risk Management and Transparency

    Ultimately, governance is about visibility. A partner with strong governance frameworks provides centralized dashboards for safety data, compliance indicators, and performance metrics.

    This transparency empowers sponsors to identify risks early, make informed decisions, and demonstrate accountability to regulators and stakeholders.

    Conclusion: Turning Governance into a Strategic Advantage

    For companies expanding globally or streamlining operations, outsourcing pharmacovigilance is not just about reducing workload. It is about embedding robust governance frameworks that ensure compliance, efficiency, and patient safety across markets.

    Partnering with QbD Group means more than delegating tasks. It means integrating proven governance structures into your operations, helping your teams focus on growth while safeguarding patients and regulatory trust.

    Effective governance transforms pharmacovigilance into a strategic advantage, keeping your company compliant, agile, and competitive on a global scale.

    Need support? Contact QbD Group today.

    Need post-market vigilance support?

    Our Global Safety Solutions supports your products post-market with vigilance, safety, and compliance.

    Explore our solutions.

    Read more

    Stay ahead in life sciences

    Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

    Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

    Subscribe to our newsletter

    Circles-banner-short

    Discover more expert content

    Blog

    Deciding Early on an Orphan Strategy: A Strategic Choice, Not a Checkbox

    Deciding whether an orphan strategy fits a development program...

    Read More

    preview_image

    Blog

    Nitrosamine Impurities in Medicinal Products: Risks and Regulatory Insights

    The emergence of nitrosamine impurities In June 2018, regulatory...

    Read More

    preview_image

    Blog

    Strategic Choices That Define a Biotech’s Path to the Clinic: First-in-Human Is Earned Long Before It Begins

    For early-stage biotech teams, the most consequential decisions are...

    Read More

    Blog

    Contamination Control Strategy (CCS) and Aseptic Process Design: Making Annex 1 Work in Real Life

    The EU GMP Annex 1 has made one message unmistakably clear: in...

    Read More

    preview_image

    Blog

    Designing Meaningful Dissolution Tests: Practical Foundations and Pharmaceutical Applications

    Designing a dissolution test is rarely a purely theoretical...

    Read More

    preview_image

    Blog

    MHRA publishes new IVD Roadmap

    The roadmap sets out broad timelines and planned activities across three key...

    Read More

    preview_image

    Blog

    Proposal for a Regulation Amending MDR and IVDR

    The proposal introduces wide-ranging changes across the device lifecycle. It...

    Read More

    preview_image

    Blog

    Draft EU Implementing Act on Notified Body Procedure Published

    The feedback period runs from 12 December 2025 to 23 January 2026. The draft...

    Read More

    preview_image

    Blog

    MDCG on Breakthrough Devices Released

    The guidance sets out the criteria for BtX designation, requiring devices to...

    Read More

    preview_image

    Blog

    New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11

    What's new? This update introduces the Acceptable Intake (AI) values for new...

    Read More

    Discover all

    Twitter Widget Iframe